Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Notes Payables (2022 - 2025)

Sonoma Pharmaceuticals has reported Notes Payables over the past 4 years, most recently at $56000.0 for Q3 2025.

  • For Q3 2025, Notes Payables fell 31.71% year-over-year to $56000.0; the TTM value through Sep 2025 reached $56000.0, down 31.71%, while the annual FY2025 figure was $220000.0, 31.89% down from the prior year.
  • Notes Payables for Q3 2025 was $56000.0 at Sonoma Pharmaceuticals, down from $139000.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $431000.0 in Q1 2023 and troughed at $56000.0 in Q3 2025.
  • A 4-year average of $196875.0 and a median of $171500.0 in 2024 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: soared 259.17% in 2023 and later crashed 31.89% in 2025.
  • Year by year, Notes Payables stood at $120000.0 in 2022, then soared by 259.17% to $431000.0 in 2023, then plummeted by 80.97% to $82000.0 in 2024, then tumbled by 31.71% to $56000.0 in 2025.
  • Business Quant data shows Notes Payables for SNOA at $56000.0 in Q3 2025, $139000.0 in Q2 2025, and $220000.0 in Q1 2025.